Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
Twitter Feed
-
Thinking about taking part in #clinicalstudies? At UCB, we’re committed to ensuring you have the information you need to make an informed decisions about your participation #InspiredByPatients #DrivenByScience https://t.co/LSMgCJrzis https://t.co/FRqhBfJC
— UCB News (@ucb_news) 23.08.2019 -
August is #PsoriasisActionMonth. At UCB, we are working to inspire those living with #psoriasis to take a more active role in caring for their disease during all stages of life. Learn more about the history of PSO and how you can take action, visit @NPF:
— UCB News (@ucb_news) 22.08.2019 -
#DYK about our commitment to improving our carbon footprint, energy efficiency, water conservation & waste control #sustainability #InspiredByPatients #DrivenByScience https://t.co/6WEtqvZyJn https://t.co/haIePd4TLA
— UCB News (@ucb_news) 21.08.2019
